Biovista information

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article appears to contain a large number of buzzwords. There might be a discussion about this on the talk page. Please help improve this article if you can. (January 2018) This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (January 2018) (Learn how and when to remove this message) (Learn how and when to remove this message)

Biovista Inc. is a private drug development services company based in Charlottesville, Virginia, US. Biovista's core business activities include drug repositioning and drug de-risking as well as disease cohort analysis, adverse event prediction and clinical hold analysis services. Biovista is also applying its technology platform to develop its own drug repositioning programs in the areas of central nervous system (CNS), diabetes/obesity, eye disorders, and oncology.^{[citation needed]}

Biovista is an active participant of European Union co-funded R&D projects spanning areas such as post-genomic clinical trials research (ACGT project),^[1] mutant mouse models for the investigation of Human Immunological Disease (MUGEN project^[1]), semantic annotation and ontology driven text mining (PARMENIDES project)^[2] and systematic knowledge discovery (ESPERONTO Project^[2]).